Morphic reports FY23 revenue $521,000, consensus $500,000

“Today, our conviction in MORF-057 as a potential oral, well tolerated, and efficacious treatment for inflammatory bowel disease is stronger than ever, based on the clear success of the EMERALD-1 trial in UC. Looking forward in 2024, we will work to translate this momentum into further progress with the GARNET phase 2 study in patients with moderately to severely active Crohn’s disease running in parallel with the EMERALD-2 phase 2b study in UC,” commented Praveen Tipirneni, CEO of Morphic. “Further, we are working to expand the pipeline of candidates generated by Morphic’s MInT Platform, most notably with our alpha5beta1 program for pulmonary hypertensive diseases and additional new projects against both integrin and non-integrin targets.”